When should systemic biologic therapy for psoriasis be discontinued?

"When should systemic biologic therapy for psoriasis be discontinued?." Journal of Dermatological Treatment, 34(1), pp.

Disclosure statement

Feldman has received research, speaking and/or consulting support from Eli Lilly and Company, GlaxoSmithKline/Stiefel, AbbVie, Janssen, Alovtech, vTv Therapeutics, Bristol-Myers Squibb, Samsung, Pfizer, Boehringer Ingelheim, Amgen, Dermavant, Arcutis, Novartis, Novan, UCB, Helsinn, Sun Pharma, Almirall, Galderma, Leo Pharma, Mylan, Celgene, Ortho Dermatology, Menlo, Merck & Co, Qurient, Forte, Arena, Biocon, Accordant, Argenx, Sanofi, Regeneron, the National Biological Corporation, Caremark, Teladoc, BMS, Ono, Micreos, Eurofins, Informa, UpToDate and the National Psoriasis Foundation. He is founder and part owner of Causa Research and holds stock in Sensal Health. Ms. Dao and Ms. Pixley have no conflicts to disclose.

Data availability statement

The data that support the findings of this study are available in the PubMed database at https://pubmed.ncbi.nlm.nih.gov/. These data were derived from the following resources available in the public domain: https://pubmed.ncbi.nlm.nih.gov/.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.